SCHEMBL10044528

SCHEMBL10044528

CC(=O)Nc1ccc(S(=O)(=O)Nc2nc3ccccc3nc2Cl)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 5/20 1.00
MAPT P10636 10/20 0.72
KDM4E B2RXH2 9/20 0.72
MEN1 O00255 7/20 0.72
KMT2A Q03164 7/20 0.72
GLA P06280 2/20 0.71
NPSR1 Q6W5P4 2/20 0.71
POLB P06746 3/20 0.70
GFER P55789 1/20 0.70
GAA P10253 5/20 0.69
TTR P02766 1/20 0.69
ALDH1A1 P00352 6/20 0.68
HPGD P15428 3/20 0.68
SMN1; SMN2 Q16637 2/20 0.67
EGFR P00533 1/20 0.67
LMNA P02545 1/20 0.67
MAPK1 P28482 1/20 0.67
HTT P42858 2/20 0.64
L3MBTL1 Q9Y468 1/20 0.64
ATIC P31939 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16091771 0.86 RXFP1 (0.76) RXFP1MAPTKDM4EMEN1KMT2A
SCHEMBL1792766 0.86 MAPT (0.85) RXFP1MAPTKDM4EMEN1KMT2A
SCHEMBL1789692 0.86 MAPT (0.85) RXFP1MAPTKDM4EMEN1KMT2A
SCHEMBL2302494 0.85 RXFP1 (0.73) RXFP1MAPTKDM4EMEN1KMT2A
SCHEMBL3582133 0.84 RXFP1 (0.72) RXFP1MAPTKDM4EMEN1KMT2A
SCHEMBL27793516 0.84 ALDH1A1 (0.74) RXFP1MAPTKDM4EMEN1KMT2A
SCHEMBL1791909 0.84 MAPT (1.00) RXFP1MAPTKDM4EMEN1KMT2A
SCHEMBL3625455 0.84 RXFP1 (0.72) RXFP1MAPTKDM4EMEN1KMT2A
SCHEMBL10044527 0.84 RXFP1 (0.72) RXFP1MAPTKDM4EMEN1KMT2A
SCHEMBL1788298 0.82 MAPT (1.00) RXFP1MAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130211076-A1 Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides MERCK SERONO S.A. GENEVA (CH) 2013-08-15 US disclosed
US-20130211076-A1 Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides MERCK SERONO S.A. GENEVA (CH) 2013-08-15 US disclosed
WO-2012052420-A1 METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES MERCK SERONO S.A. GENEVA (CH) 2012-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130211076-A1 Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides STS, NQO2, ASNS RXFP1 3539/4885MAPT 4392/4885KDM4E 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.